Damora Therapeutics, Inc. (DMRA): Nasdaq/NYSE listing notice — Galecto receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure

Damora Therapeutics, Inc.

Nasdaq notified Galecto that common stock bid price closed below $1.00 for 30 consecutive business days.
Company has until March 25, 2024 to regain compliance with Minimum Bid Price Requirement.
If not cured, Galecto may qualify for a second 180-day period by transferring to Nasdaq Capital Market.
Galecto may consider a reverse stock split to regain compliance, but no assurance of success.
Common stock symbol GLTO continues trading on Nasdaq Global Select Market pending compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Damora Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

September 27, 2023, Galecto, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, a

View on SEC.gov

Browse all listing & compliance notices →

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-051118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.